Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00060151 · ClinicalTrials.gov registry record · Phase 1
GW786034 in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00060151 is a Phase 1 study that has completed, run by Case Comprehensive Cancer Center.
The verdict
NCT00060151, a Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: GW786034 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of GW786034 in treating patients with advanced solid tumors.
Interventions
- DRUG pazopanib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-12 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00060151
The ClinicalTrials.gov registry entry for NCT00060151 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pazopanib hydrochloride is the first listed.
NCT00060151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00060151 about?
NCT00060151 is a clinical study titled "GW786034 in Treating Patients With Advanced Solid Tumors". RATIONALE: GW786034 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of GW786034 in treating patients with advanced solid tumors.
What is the current status of trial NCT00060151?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-12. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00060151?
The interventions under investigation include: pazopanib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00060151?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.